Needham & Company Upgrades Alnylam Pharmaceuticals (ALNY) to 'Buy' Based on Expected 2011 Clinical Pipeline News Flow and Low Valuation
Tweet Send to a Friend
Needham & Company upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Hold to Buy. PT $16.
Needham analyst says, "We are upgrading ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "We are upgrading ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
